Dr. Kurtz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Mayo Clinic College of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2010 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 129 citationsDynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.David M. Kurtz, Mohammad Shahrokh Esfahani, Florian Scherer, Joanne Soo, Michael C. Jin
Cell. 2019-07-25 - 26 citationsCirculating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.Jurik A Mutter, Stefan K Alig, Mohammad S Esfahani, Eliza M Lauer, Jan Mitschke
Journal of Clinical Oncology. 2023-03-20 - 7 citationsA human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.Jenna M Kastenschmidt, Joseph G Schroers-Martin, Brian J Sworder, Suhas Sureshchandra, Michael S Khodadoust
Cell Stem Cell. 2024-03-07
Abstracts/Posters
- An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell LymphomaDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel TherapyDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCLDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin LymphomaDecember 13th, 2022- Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and ExpositionNovember 3rd, 2022
- Advances in Malignant Lymphoma: Discoveries from Precursors to ProgressionJune 20th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
